India's Aurobindo Pharma is leading the race to acquire Prague-based generic drugmaker Zentiva in a deal valued at up to $5.5 billion, according to multiple reports including the Economic Times. This acquisition would represent the largest-ever buyout by an Indian pharmaceutical company and marks a significant step in Aurobindo Pharma's global expansion strategy. Zentiva is currently owned by private equity firm Advent International. The deal is expected to reshape India's presence in the global healthcare and pharmaceutical sectors.